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The main risk factor for transmission of bloodborne viruses (BBVs) in drug users in Ireland is injecting opioids, 
particularly heroin. Estimates from a 2014 capture-recapture study indicate that there are just under 19,000 
problem opioid users in Ireland, with over 70% living in Dublin1. This is similar to the estimate from a previous 
capture-recapture study carried out in 20062. However, the age profile of opioid users changed significantly 
between 2006 and 2014. Results from the 2014 study indicate that 60% of Ireland’s opioid users are aged 
between 35 and 64 years compared to less than one third in the 2006 study. Furthermore, only 6% were 
aged between 15 and 24 years compared to over one fifth in the previous study. These results indicate a high 
prevalence of opioid use among older drug users, but a declining incidence of problem opioid use in Ireland.
Trends from the National Drug Treatment Reporting System (NDTRS) indicate a steady decline in new 
entrants to treatment who reported opioids as their primary problem drug between 2009 and 2016, and a 
decrease in the proportion who inject3-6. However, cocaine and benzodiazepine use has increased in recent 
years. These are associated with a lower risk of BBVs, as they are less likely to be injected. However, 2% of 
those entering treatment for cocaine in 2015 were currently injecting and a further 12% had injected drugs in 
the past. Cocaine was also hypothesised to be responsible for high rates of HIV infection in a cohort of drug 
users in an inner-city area of Dublin in a 2001 study7. Furthermore, people who use cocaine, benzodiazepines 
and other drugs, such as new psychoactive substances, image and performance enhancing drugs, or chemsex 
drugs, may be less likely to self-identify as problem drug users and less likely to avail of BBV testing, harm 
reduction and drug treatment.
Over three quarters of diagnosed cases of hepatitis C in Ireland are in people who inject drugs (PWID) 8,9. Data 
from statutory notifications, studies in opioid substitution treatment (OST) settings and studies in prisons 
indicate a high prevalence, but declining incidence, of hepatitis C in opioid users in Ireland7-31. OST is readily 
available in Ireland, particularly in the greater Dublin area, and the uptake of BBV testing in OST settings is 
reported to be high. With the advent of highly effective (>95% cure) direct-acting antiviral drugs, hepatitis C 
elimination is now achievable in Ireland32. Implementation of the National Hepatitis C Screening Guidelines33 
and the Clinical Guidelines for OST34 will be important in maximising the proportion of cases diagnosed and 
treated and further reducing the incidence of hepatitis C infection in Ireland.
Data from statutory notifications show that the number of new HIV diagnoses in PWID is also decreasing in 
Ireland9. Data from the National Virus Reference Laboratory (NVRL) in 2016 showed ongoing transmission 
of HIV in this cohort, but the numbers were small.35 Viral suppression is now achievable for most diagnosed 
and treated cases of HIV36,37. Screening and early treatment are essential to prevent onward transmission 
and to decrease morbidity and mortality. However, a recent outbreak of HIV among homeless PWID in Dublin 
highlighted the ongoing vulnerability of this population to infection and future outbreaks.38
Results from studies in OST settings and from statutory notifications data indicate a low prevalence and 
incidence of hepatitis B in PWID in recent years 9,13,18,24. This is likely to be due to a combination of immunity 
post-infection in the past and good vaccine coverage. However, there is a need to collect better data on 
vaccine uptake, to encourage vaccination in OST settings and to increase the availability of vaccination in 
other settings, such as through needle exchange services.
Currently, in most addiction treatment clinics and prisons, information on BBV screening uptake and 
laboratory results has to be extracted manually, for each patient, from paper records and scanned images. 
Computerisation of the drug treatment services, with an emphasis on the importance of recording laboratory 
results in an extractable format, would greatly enhance monitoring and data reporting. There are also missed 
opportunities in relation to Dublin-based needle exchange services. Although needle exchange is designed to 
be a low-barrier service, it would be useful to collect a minimum dataset on the cohort at highest risk of BBVs. 
It would also be beneficial to service users if on-site vaccination, BBV screening and referral to other services 
were available through needle exchange services 39,40.
Summary
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1. Introduction
People who use drugs are at risk of acquiring viral and bacterial infectious diseases, which can cause 
significant morbidity and premature mortality. Surveillance of drug use and drug-related bloodborne 
viruses (BBVs) is essential for monitoring the impact of prevention and harm reduction programmes. A 
report on BBVs in PWID was published by the Health Research Board (HRB) in 200641. Since then, there 
have been many changes in the patterns of drug use, in addiction services, and in the incidence and 
prevalence of BBVs in drug users in Ireland.  
There have also been significant changes in the efficacy of, and access to, hepatitis C and HIV treatment. 
Treating hepatitis C, with new direct acting antiviral (DAA) drugs, results in a cure for over 95% of patients32. 
The HSE has established a National Hepatitis C Treatment Programme (NHCTP) to ensure that people 
living with hepatitis C are offered effective treatment in a structured way. Elimination of hepatitis C is now 
achievable in Ireland (described in more detail in section 5.1 box 1). Recent advances in HIV treatment and 
prevention include the recommendation in 2017 from the HSE that all people newly diagnosed with HIV 
should be offered antiretroviral therapy (ART), regardless of their stage of HIV infection. (See section 5.2 
box 3 for further information on HIV treatment). 
The aim of this report is to summarise what is currently known about drug-related BBVs in Ireland. The 
report focuses on hepatitis C, HIV and hepatitis B and begins by outlining problem drug use associated 
with an increased risk of these infections. Problem drug use is defined as ‘injecting drug use, or long 
duration, or regular use, of opioids, cocaine and/or amphetamines’ (http://www.emcdda.europa.
eu/stats07/PDU/methods). Trends in the number of drug users and drug treatment services are also 
described.  Available information on the incidence and prevalence of hepatitis C, HIV and hepatitis B in 
drug users is summarised. Gaps in knowledge and opportunities for improvements in the way information 
is collected or recorded are identified. 
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2. High-risk drug use in Ireland
Injecting or smoking heroin, snorting cocaine and using benzodiazepines or new psychoactive substances 
are common among high-risk drug users in Ireland, particularly among homeless people and those living in 
socioeconomically deprived areas.  People who use drugs are at high risk of BBVs, tuberculosis and bacterial 
infections at injection sites. Alcohol misuse and mental health problems are common co-morbidities. 
Discrimination and the stigma of addiction are ongoing issues, and some people who use drugs may find it 
difficult to access addiction services due to their chaotic lifestyles.
the following sources of information were used to describe high-risk drug use in ireland:
• Capture recapture studies carried out in 200142, 20062 and 20141
• HRB National Drug Treatment Reporting System (NDTRS)
• Central Treatment List (CTL)
• Other published studies and Irish reports
2.1 opioids
The most significant risk factor for the transmission of BBVs in drug users in Ireland is through opioid use, in 
particular through injecting heroin. Heroin first became widely available in Ireland in the late 1970s and early 
1980s. Its use was initially concentrated in areas of local authority housing in deprived north and south inner-
city areas of Dublin. Studies in these areas at the time found that 9-10% of 15-24 year olds were using heroin 
and that most were injecting10,11,14. Unsafe injecting practices in small communities of drug users posed a high 
risk of BBVs and significant proportions of these early heroin users became infected with hepatitis C, HIV and 
hepatitis B.  In a 25 year longitudinal study (1985-2010) of 82 early heroin users in a south inner-city area 
of Dublin, 71% became infected with hepatitis B and 63% became infected with HIV over the time period of 
the study. A significant number were not tested for hepatitis C as there was no test available when the study 
began, but of those subsequently tested two thirds were positive27.
The opioid epidemic plateaued in the mid-1980s, but there was a resurgence in the 1990s and heroin use 
spread more widely to other areas of Dublin, including newer suburban local authority housing estates10,14. 
Three capture-recapture (CRC) studies, commissioned by the National Advisory Committee on Drugs and 
Alcohol (NACDA), and carried out between 2001 and 2014, indicate that there are now a significant number 
of problem opioid users in Ireland1,2,42. 
The first two studies were carried out in 200142 and 20062. The data sources used were the Central Treatment 
List of clients on methadone (CTL), the Hospital In-Patient Enquiry scheme (HIPE) and the Garda PULSE 
database.  A third study, commissioned in 20141, used four data sources:  drug treatment clinic data, 
information from general practice, prison records and statistics provided by the Irish Probation Service. 
Table 1 (CRC 2014) shows the most recent prevalence estimates of opioid use in Ireland. Data from this study 
indicated that the national prevalence of opioid users in 2014 was between 18,720 and 21,4541. The point 
estimate was 18,988, giving a rate of 6.18 per thousand population aged 15-64 years (95% CI: 6.09-6.98). 
Sixty nine percent were male1. 
Seventy one per cent of opioid users lived in Dublin. The estimates for Dublin were 13,458 (95% CI: 12,564-
14,220), suggesting a population rate of 15.15 per thousand population. The prevalence for the rest of Ireland 
(excluding Dublin) was determined to be 5,530 (95% CI: 5,406-8,023), 2.53 per thousand population1. 
In terms of regional differences by county, County Sligo had the lowest prevalence of opioid use with a rate 
of 0.37 per thousand population (95% CI: 0.21-1.73). Other counties with prevalence rates lower than 1.0 
8
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per thousand were Donegal, Leitrim, Mayo and Monaghan. With regard to regional differences by city, after 
Dublin, Limerick had the highest rate of use at 8.82 per thousand population (95% CI: 7.11-13.16) followed by 
Waterford (6.72, 95% CI: 5.24-15.12) and Cork (5.67, 95% CI: 4.91-6.71). Galway had the lowest city prevalence 
of opioid use at 1.93 per thousand (95% CI: 1.55-2.73)1.
The 2014 CRC study collected data from all sources for a four year period (2011-2014)1, allowing opioid use 
prevalence estimates for 2014 to be compared with estimates from 2011, 2012 and 2013. There was an increase 
each year, rising from 17,387 in 2011 to 18,988 in 2014 (figure 1). However, this was not a statistically significant 
increase over time. Other trends observed include the following:
•  There was a non-significant decline in opioid use both inside and outside of Dublin when compared 
to 2006 (table 2). 
•  The proportion of opioid users aged 15-24 years also declined (6% in 2014 compared to 21% in 2006).
•  There was an increase in the proportion of opioid users who were aged between 35 and 64 years 
(60% in 2014 compared to less than one-third in 2006), suggesting an ageing cohort.
Although findings from the 2014 CRC study suggest that the prevalence of problem opioid use in Ireland 
may have stabilised, it should be noted that estimates remain high, with comparable international studies 
suggesting that rates of use remain amongst the highest in Europe (figures 1 & 2). In addition, the authors of 
the most recent CRC study highlight that there is limited validity in making direct comparisons with previous 
CRC studies conducted in Ireland, due to the use of different data sources. Furthermore, none of the slight 
decreases observed was statistically significant1.
table 1. summary of prevalence estimates of opioid use in 15-64 year olds, in ireland, 2014 
area estimate lower bound upper bound Rate/1000 population
Dublin 13,458 12,564 14,220 15.15
Rest of Ireland 5,530 5,406 8,023 2.53
State total 18,988 18,720 21,454 6.18
age group
15-24 years 1,092 1,076 1,234 1.88
25-34 years 6,672 6,578 7,539 8.84
35-64 years 11,224 11,065 12,681 6.46
gender
Female 5,966 5,882 6,741 3.86
Male 13,022 12,838 14,713 8.52
Source: NACDA, 20171 
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Figure 1. national estimates of the annual prevalence rate of high-risk opioid use 
Source: EMCDDA, 2018
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table 2. estimated prevalence of opioid use, in 15-64 year olds, in ireland for 2001, 2006 and 2014
area 2001 estimate
2001 rate/1000 
population
2006 estimate
2006 rate/1000 
population
2014 estimate
2014 rate/1000 
population
Dublin 12,456 15.9 14,909 17.6 13,458 15.15
rest of ireland 2,225 1.2 5,886 2.9 5,530 2.53
state total 14,681 5.6 20,790 7.2 18,988 6.18
Source: NACDA, 20171
Figure 2. national estimates of the annual prevalence rate of high-risk opioid use in europe
Source: EMCDDA, 2018
national Drug treatment reporting system (nDtrs)
Surveillance of treated problem drug use in Ireland is carried out using an on-line epidemiological database 
(NDTRS). This is co-ordinated by the Health Research Board (HRB) on behalf of the Department of Health 
(DoH).  The NDTRS reports on treatment episodes, rather than individuals, per calendar year. It was established 
in 1990 in the Greater Dublin Area and was extended to cover all areas of the country in 1995. 
Although it is evident that there is a significant opioid problem in Ireland, trends from the NDTRS indicate 
that the incidence of treated opioid use (mainly heroin) and of injecting opioids has declined3-6. Since a peak 
in 2009, there has been a steady decline in the total number of new entrants to treatment reporting opioids 
as their main problem drug (38% decrease between 2009 (n=1,523) and 2016 (n=950)). In recent years, there 
were also significant differences between those who were entering drug treatment for the first time and 
those who had been previously treated. Twenty seven percent of first time entrants to drug treatment in 2016 
reported opioids as their main problem drug compared to 60% of those who had been previously treated 
and were re-entering treatment in 2016.3-4 New entrants to treatment were also less likely to have injected. 
These trends indicate that more recent problem drug users are less likely to be opioid users and that fewer 
are injecting. These data support the results from the 2014 CRC study, which indicated an ageing cohort of 
opioid users in Ireland1,5. Figure 3 shows trends in the number of new entrants to treatment for heroin use 
(most common problem opioid used in Ireland).
summary
The 2014 CRC study estimated that there are approximately 19,000 problem opioid users in Ireland, 
with no significant change since the 2006 CRC study. The rate of opioid use in Ireland is still among the 
highest in Europe. Seventy one percent of problem opioid users lived in Dublin and over two thirds were 
male. Sixty percent of problem opioid users were are aged between 35 and 60 years in the 2014 study, 
compared to less than one third in 2006. This, combined with NDTRS data showing a decrease in the 
incidence of opioid use, indicates an ageing cohort of opioid users in Ireland. 
The number of entrants to drug treatment reporting cocaine and benzodiazepines as their main problem 
drug has increased in recent years. Cocaine, benzodiazepines and NPS are associated with a lower risk of 
BBVs compared to opioids, as these drugs are less likely to be injected. However, people who use these, 
or image and performance enhancing drugs, may be less likely to access BBV screening and hepatitis B 
vaccination.
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Figure 3. number of first time entrants to treatment for heroin use 
(main problem drug) in ireland, 2006-2016
Source: EMCDDA, 2018
2.2 Polydrug use
Over 60% of entrants to drug treatment in 2016 reported problem polydrug use (individual taking a combination 
of two or more drugs)4. Polydrug use was also found to be very common in a 2016 audit of hepatitis C testing 
in addiction treatment centres in CHO731. In this audit, almost all (99%, n=375) of the 379 respondents with 
risk factor information were opioid users, 79% (n=298) of whom were either current injectors or had injected 
in the past. However, 59% (n=224) also used benzodiazepines, 56% (n=214) used cocaine and 5% (n=19) used 
new psychoactive substances (NPS). 
2.3 Cocaine
Treatment data from the NDTRS show that the number of treatment entrants reporting cocaine as their main 
problem drug tripled between 2004 (n=353) and 2016 (n=1138). Twelve percent of treatment entrants in 2016 
reported cocaine as their primary problem drug and 26% of those who reported a different main problem 
drug reported cocaine as an additional problem drug4. Furthermore, on routine drug screening, the average 
positivity rate for cocaine among clients attending opioid substitution treatment (OST) clinics in Dublin in 
June 2017 was 18%, and over a third of clients in one clinic tested positive43. Cocaine is most commonly taken 
by snorting and less commonly by injecting. Some published studies have reported an association between 
snorting cocaine and hepatitis C infection and others have found no association33. However, the risk of BBVs 
would be expected to be significantly increased in those who use cocaine and have a history of injecting. Two 
percent of those entering treatment for cocaine in 2015 were currently injecting drugs and a further 12% had 
injected drugs in the past (NDTRS interactive tables, accessed August 2018, https://www.drugsandalcohol.
ie/tables/). Figure 4 shows trends in the number of new entrants to treatment for cocaine use.
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Figure 4. number of first time entrants to treatment for cocaine use 
(main problem drug) in ireland, 2006-2016
Source: EMCDDA, 2018
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2.4 Benzodiazepines
Ten percent of entrants to drug treatment in 2016 reported benzodiazepines as their main problem drug4,5. 
However, benzodiazepines are much more commonly reported as an additional problem drug among polydrug 
users and over a third (37%) of treatment entrants reported benzodiazepines as an additional problem drug in 
2016. The misuse of benzodiazepines increases the risk of opioid overdose and is associated with a higher risk 
of acquiring HIV infection, experiencing anxiety and depression, and having poorer drug treatment outcomes 
and poorer social functioning44.
2.5 New psychoactive substances (NPS)
The percentage of entrants to treatment in 2016 who reported NPS as their primary problem drug (<1%) 
or an additional problem drug (2%) was low4 However, NPS are still considered a threat as they may lower 
inhibitions and lead to more risk taking behaviour, in terms of sharing injecting equipment used for other 
drugs, and high-risk sex. NPS drug use during sex (chemsex) among men who have sex with men (MSM) is 
a cause for concern because of the direct effects of the drugs themselves (e.g. overdose, acute intoxication, 
addiction, loss of capacity to give sexual consent), and because of an increased risk of transmission of sexually 
transmitted infections (STIs). The impact of chemsex is discussed in greater detail in section 6.3. 
Although many NPS are taken orally, some may be injected, significantly increasing the risk of BBVs. An 
outbreak of acute HIV infections in PWID in Dublin, between 2014 and 2015, was found to be associated with 
injecting the synthethic cathinone, ‘snow blow’38. This outbreak is further described in section 5.2, box 2.
2.6 Image and performance enhancing drugs (IPED)
Limited data are available on the prevalence of BBVs in people who inject image and performance enhancing 
drugs (IPED) in Ireland. A small study of 89 IPED users attending Merchant’s Quay Ireland for harm reduction 
services found that about half had been tested for BBVs45. Of those tested, 10% self-reported that they had 
hepatitis C and none reported testing positive for HIV or hepatitis B. Almost all study participants (97%) 
reported lifetime injecting use of anabolic-androgenic steroids, but polydrug use was also very common. 
Sixty eight percent reported that they had used cannabis, 57% had used cocaine, 6% had injected cocaine, 
36% had used benzodiazepines, 11% had injected heroin and 2% had injected NPS. All of those who tested 
positive for hepatitis C had also injected psychoactive drugs.  Although there is currently insufficient evidence 
to ascertain the risk of BBVs in IPED users in Ireland, this may emerge as an issue in the future and it is 
important that screening is improved and that hepatitis B vaccination is encouraged.
summary
The 2014 CRC study estimated that there are approximately 19,000 problem opioid users in Ireland, 
with no significant change since the 2006 CRC study. The rate of opioid use in Ireland is still among 
the highest in Europe. Seventy one percent of problem opioid users lived in Dublin and over two 
thirds were male. Sixty percent of problem opioid users were aged between 35 and 60 years in the 
2014 study, compared to less than one third in 2006. This, combined with NDTRS data showing a 
decrease in the incidence of opioid use, indicates an ageing cohort of opioid users in Ireland. 
The number of entrants to drug treatment reporting cocaine and benzodiazepines as their main 
problem drug has increased in recent years. Cocaine, benzodiazepines and NPS are associated 
with a lower risk of BBVs compared to opioids, as these drugs are less likely to be injected. However, 
people who use these, or image and performance enhancing drugs, may be less likely to access BBV 
screening and hepatitis B vaccination.
12
D Rug -Rel ateD blo o DboRne vIRuSeS I n IR el anD 2018
3. Drug treatment and harm reduction services
Needle and syringe programmes (NSP) were introduced in Ireland in 1989 and access to opioid substitution 
treatment (OST) was expanded. Prior to 1989, there was limited access to OST (e.g. for pregnant women and 
those with severe health problems, including HIV). There was a move in the early 1990s to provide a broader 
range of harm reduction services for those who were opioid dependent. This was specifically driven by a public 
health approach to the issue of HIV prevalence in this population. Consequently, addiction services were 
greatly expanded during the 1990s13,27 particularly after the publication of the 1996 Ministerial Task Force 
report on measures to reduce the demand for drugs46. This report identified harm reduction measures such 
as OST, rehabilitation, and education and prevention as key priority areas in tackling the drugs problem in 
Ireland. Harm reduction remained a key focus area in National Drugs Strategy reports in 2001, 2009 and 
201747,48,49. 
A complete list of drug treatment services is available from http://www.services.drugs.ie/  and further detail 
is contained in the EMCDDA 2018 report, available from 
http://www.emcdda.europa.eu/countries/drug-reports/2018/ireland_en
the following sources of information were used to describe drug treatment and harm 
reduction services:
• Central Treatment List (CTL)
• HSE Annual Report and Financial statements, 201750
• Evaluation of the pilot stage of the Pharmacy Needle Exchange Programme in Ireland40
• Other published studies and Irish reports
3.1 opioid substitution treatment (ost) 
OST using methadone is provided by specialised HSE outpatient treatment clinics/satellite clinics (n=80), 
through specially trained general practitioners (GPs) in the community (n=376) and in prisons (n=10). All OST 
patients are registered on the CTL, which is an administrative database, established to regulate the dispensing 
of methadone. It is a complete register of all patients receiving methadone (as treatment for problem opioid 
use) in Ireland. The number of clients on this list has increased each year since 2006 (figure 5). By the end of 
2017, over 10,000 patients were receiving OST, 53% through specialised clinics, 41% through community GPs 
and 6% in prisons. OST is readily available in Ireland, with an average waiting time from referral to assessment 
in 2017 of 5.5 days. In 2017, 99% of adults commenced treatment within one month of assessment, and 97% 
of those aged less than 18 years commenced treatment within one week of assessment50. However, there may 
be regional variations in the availability and waiting times for OST. Seventy percent of clients on the CTL in 
2017 were male and 72% of all clients were 35 years or older.
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Figure 5. trends in the number of clients in ost in ireland, 2006-2016
Source: EMCDDA, 2018
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3.2 needle and syringe programmes (nsP)
There are three models of NSP in use in Ireland:  
• Static – 24 sites mainly in Dublin city 
• Outreach – 14 sites mainly in counties Dublin, Kildare, Laois, Offaly, Waterford and Wicklow 
• Pharmacy – 111 sites in regions outside Dublin, Kildare and Wicklow. 
Merchants Quay Ireland and Ana Liffey Drug Project operate NSP in the Dublin area and within Ireland as 
a whole.  Data on the number of syringes exchanged from static and outreach sites in the Dublin area were 
unavailable for this report. 
Outside of the greater Dublin area, needle exchange services are almost exclusively pharmacy-based, but 
this scheme has not extended to Dublin-based pharmacies yet. Monthly and annual data are only recorded 
in relation to the pharmacy-based needle exchange programme. The number of pharmacies providing 
needle exchange packs increased from 42 in 2011 to 110 by the end of 2017. Almost 2,000 (n=1,933) unique 
individuals attended pharmacy-based needle exchanges in 2017 and an average of 13 needle/syringe packs 
were distributed per person per month (168 per person for the year)50. This is less than the target for 2020 
(200 syringes per PWID per year), set in the WHO Euro Action plan for hepatitis51.   
Currently, BBV testing and hepatitis B vaccination are not available at needle exchange sites in Ireland, 
and integrated needle exchange services are not available at most OST sites.  A study which evaluated the 
pharmacy-based needle exchange programme found that approximately one-third of clients reported never 
having been tested for BBVs and almost half (49%) of clients reported having used a needle with which 
someone else had already injected, with 28% having done so in the past month40. With these figures in mind, 
the study authors made a number of recommendations which included the following: 
•  To consider offering in-pharmacy testing for BBVs. Where this is not possible, to ensure that pharmacy 
staff are provided with sufficient information on local services to enable efficient referral processes and 
signposting. 
•  To provide a wider range of equipment or packs suitable for all clients and look at potentially providing ‘pick 
and mix’ services, in addition to pre-prepared packs, to better meet client needs. 
•  To ensure that pharmacy staff have sufficient training and knowledge about drug use and health-related 
issues to confidently provide harm reduction advice and support. 
•  To oversee the transition from a paper-based monitoring system to an electronic data monitoring system 
to be used by all participating pharmacies. 
3.3 supervised injecting facilities (siF)
Supervised injecting facilities (SIFs) have been operating in several European countries for the past 30 years. 
Harm reduction is provided at these sites as drug users can safely inject drugs using sterile equipment under 
the supervision of trained personnel.  It has been found that SIFs are very effective at reaching the most chaotic 
of drug users, who are often homeless, providing these high-risk, vulnerable and marginalised individuals 
with easier access to information, support and services. In 2017 the Irish Government passed “The misuse of 
drugs (supervised injecting facilities) Act” which allows the Minister for Health to grant licences for SIFs to be 
set up in Ireland. Once established, these will be a major extension to the harm reduction services available 
to drug users in Ireland. (Press Release Department of Health 2017).  The HSE has entered into a tendering 
process for a service to provide a SIF subject to the necessary local authority planning laws.
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The following sources of information were used to describe guidelines for BBV testing and 
immunisation in drug users:
•  Clinical Guidelines for Patients on OST34,52
•  Immunisation Guidelines for Ireland53 
•  National Hepatitis C Screening Guidelines33
•  Healthcare Standards for Irish Prisons54
•  National Sexual Health Strategy (2015-2020)55
The latest clinical guidelines for patients on OST were published in 201734. These recommend that all patients 
attending OST services be screened for hepatitis A, hepatitis B, hepatitis C and HIV, even if they are not 
injecting drug users and that all be vaccinated against hepatitis A and B. Repeat testing is recommended for 
those who initially test negative for HIV if they report engaging in behaviours that would put them at ongoing 
risk of infection. The guidelines also recommend referral to specialist services and treatment, as clinically 
appropriate, for patients who test positive for hepatitis C or HIV. These replaced the 2008 Irish College of 
General Practitioners (ICGP) guidelines52 but the earlier guidelines also recommended testing for BBVs and 
hepatitis A and B vaccination, and this has always been common practice in the addiction services.  The 
Immunisation Guidelines for Ireland also recommend vaccination against hepatitis A and B for non-immune 
PWID53.
Similar testing recommendations were made in the 2017 National Hepatitis C Screening Guidelines33, which 
include a recommendation to offer hepatitis C testing to all of those who have ever injected any illicit drugs 
and to re-test those who test negative every 6-12 months if they remain at risk of infection.  These guidelines 
also recommend testing drug users who have never injected, if there is a possibility of transmission of HCV by 
the route of administration, and offering testing to all prison inmates on entry to prison or on request. 
The Healthcare Standards for Irish Prisons recommend screening for HIV and hepatitis for all inmates who 
volunteer a background history of risk factors for these diseases54. Immunisation against hepatitis A and 
hepatitis B is recommended for all prison inmates53,54. The prison healthcare standards are currently being 
revised. In practice, BBV testing and hepatitis A and B vaccination are offered to all inmates on committal, 
regardless of declared risk factors, or at other times if requested.
As a consequence of these policies and guidelines, testing for BBVs, particularly hepatitis C, has been reported 
to be high (93-95%) for patients in OST in studies published in recent years29,30,31. However, uptake of testing 
may be lower in some settings. Cullen et al reported that just over three quarters (77%) of clients attending 25 
general practices for OST had been tested for hepatitis C25, but data for this study were collected in 2002 and 
testing may have improved since then.  Routine reporting of BBV screening uptake and results is not possible 
for most addiction treatment clinics in Ireland as most services are not computerised. Even in some that are, 
laboratory results are often scanned, rather than entered into the system in an extractable format.
Studies reporting information on hepatitis B immunisation status indicate that vaccination coverage is not 
as high as would be expected given the recommendations to vaccinate prisoners and PWID. Only 37% of 
prison inmates reported receiving at least one dose of hepatitis B vaccine in a 2011 prison study. However, 
prisoners with a history of injecting drug use were more likely to have been vaccinated, with over half (54%) 
4. Guidelines for testing for BBVs and immunisation
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reporting having been at least partially vaccinated28. Similar results were reported in a study of OST clients 
attending level 1 and level 2 GPs (GPs with training in substance misuse, who can prescribe OST), with just 
under half (49%) of patients having received at least one dose of hepatitis B vaccine and only 23% being fully 
immunised25.  
Immunisation levels may be higher in patients attending OST clinics. In an older study of a sample of clients 
attending 21 OST clinics in the greater Dublin area, 81% of those who were not infected with hepatitis B had 
received at least one dose of vaccine and 69% had been fully vaccinated. Of the remaining 19%, 4% had been 
offered immunisation and had refused and 15% had no evidence of vaccination or past infection24.  
There is no adult register for recording hepatitis B vaccine uptake and information on vaccination may not 
be recorded systematically in medical notes. In some studies, data on hepatitis B vaccination status is self-
reported and may not be accurate. Anecdotally, the practice in OST settings is to vaccinate and it is likely that 
the actual vaccination coverage is higher than reported here. However, hepatitis B vaccination levels could 
be optimised by ensuring that an accelerated schedule is used and also by offering vaccination in needle 
exchange and other non-OST settings.
The National Sexual Health Strategy (2015-2020) recommended that national HIV testing guidelines should 
be developed55 and the HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) has established a 
working group to develop these. They will be guided by the updated HIV and hepatitis testing guidelines 
which are currently being prepared by the European Centre for Disease Prevention and Control (ECDC). 
Current guidance from the EMCDDA and ECDC recommends regularly offering hepatitis B, hepatitis C and 
HIV tests to PWID at least once every 6 to 12 months56.
Summary
OST availability and coverage is high in Ireland. Guidelines recommending screening for BBVs in 
OST and prison settings are in place and screening is reported to be carried out routinely in these 
settings. Those found to be positive can avail of hepatitis C and HIV treatment, which should result 
in significantly improved health outcomes and decreased transmission of these BBVs to others. The 
lack of computerisation in most addiction treatment clinics means that data on BBV screening and 
results, and hepatitis B vaccination uptake, cannot be routinely reported. 
Although data are available from pharmacy-based needle exchange programmes outside of the 
Dublin area, there are significant gaps in knowledge in relation to Dublin-based needle exchange 
services. It is not currently possible to assess if sufficient needle/syringe packs are distributed to 
meet the needs of service users or to monitor progress towards the targets set in the WHO Euro 
Action Plan for Hepatitis. The lack of availability of BBV screening and vaccination through needle 
exchange services is also a missed opportunity for harm reduction in the cohort of drug users at 
greatest risk of infection.
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People who use drugs are at risk of acquiring viral and bacterial infectious diseases, which can cause significant 
morbidity and premature mortality. Aside from bacterial infections at injection sites, hepatitis C, HIV and 
hepatitis B are the most common infections associated with illicit drug use. In this section,
each of these three viral infections is described separately. Bacterial infections are not covered in this report.
the following sources of information were used to describe the trends and the burden of 
disease from these viruses in drug users:
• Surveillance data from the Health Protection Surveillance Centre (HPSC)
• Data from the Irish National Drug-Related Deaths Index (NDRDI) 
• A review of published studies and reports
For the literature review, the primary areas of focus were incidence and prevalence of BBVs, 
BBV-related mortality and morbidity, and BBV-related risk behaviours of people who use 
drugs. Four electronic databases were searched (PubMed, EMBASE, Scopus, Web of Science) 
for peer-reviewed articles. Google Scholar, Lenus and the HPSC webpage were searched for 
scientific grey literature. A MeSH and keyword search strategy was used. The searches were 
refined to articles in English, published between 1995 and 2018. 
5.1 Hepatitis C
The hepatitis C virus (HCV) was first identified in 1989. It primarily affects the liver, but can also have 
extrahepatic manifestations. The acute stage of infection is usually asymptomatic, but around three quarters 
of those infected develop chronic infection, which can cause cirrhosis of the liver, hepatocellular carcinoma 
(liver cancer) and liver failure. Between 10 and 20% of those who are chronically infected develop cirrhosis 
after 20-30 years of infection57. Liver disease progression is faster in those with high alcohol consumption, in 
males and in those who are co-infected with HIV and/or hepatitis B57. 
Diagnosed cases of hepatitis C
national virus reference laboratory, 1989-2004
The National Virus Reference Laboratory (NVRL) carried out approximately 95% of confirmatory tests for 
hepatitis C in Ireland between 1989 and 2004. A joint HPSC/NVRL study, which involved converting NVRL 
specimen-based data into person-based data, estimated that over 10,000 people (n=10,384) were diagnosed 
with hepatitis C between 1989 and 20048. Risk factor information was available for over three quarters of 
these cases and 80% were current or former PWID (figure 6).
5. Drug-related bloodborne viruses
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Figure 6. number of nvrl-confirmed cases of hepatitis C by year of diagnosis and 
reported risk factor, 1989-2004
Source: Adapted from Thornton et al. Determination of the burden of hepatitis C virus infection in Ireland. Epidemiol Infect 
2012, 140:1461-1468.
Hepatitis C notifications, 2004-2017
Hepatitis C became a notifiable disease in Ireland in 2004. This means that all clinicians and laboratory 
directors are required to report all diagnosed cases of hepatitis C to their local Department of Public Health. 
Regional data are entered by the Department of Public Health, or uploaded directly by the laboratory, onto 
the national computerised infectious disease reporting system (CIDR). HPSC is responsible for reporting 
on notification data at a national level. Enhanced surveillance data on hepatitis C, including risk factor 
information, have been collected since 2007. 
Almost 15,000 (n=14,700) cases of hepatitis C were notified between 2004 and 2017 (figure 7)58. Cases which 
were diagnosed pre-2004 are notifiable if the case comes to the attention of a clinician/laboratory director 
and has not been previously notified; therefore not all cases notified since 2004 were diagnosed since 2004. 
The number of hepatitis C notifications peaked in 2007 and decreased by almost 60% between 2007 and 
2017. Information on risk factor was available for just over half of cases notified since 2007 (5595/10975), of 
whom 80% were PWID (figure 7).  In 2017, 621 cases (13/100,000 population) of hepatitis C were notified to 
HPSC. Risk factor data were available for 48% (n=299), of whom 70% (n=209) were PWID. The proportion of 
cases attributed to injecting drug use has decreased in recent years (80% in 2014, 75% in 2015, 68% in 2016 
and 70% in 2017). However, as risk factor data were only available for half of hepatitis C notifications, this 
trend should be interpreted with caution. The median age at notification for hepatitis C cases identified as 
drug users has increased steadily over the past ten years, from 32 in 2008 to 39 in 2017. Over a third of cases 
notified in 2017 were aged 30-39 years and 50% were 40 years or older (figure 8). The increase in the age of 
notified cases is likely to indicate a declining incidence of hepatitis C among younger drug users. Seventy two 
percent of cases of hepatitis C attributed to drug use were male.
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Figure 7. number of notifications of hepatitis C by year of notification and reported risk 
factor, 2007-2017 
Source: HPSC                                                                                                                                                                                    
*Case definitions changed in 2012 to specifically exclude cases known to have resolved infection
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Figure 8. number of notifications of hepatitis C with injecting drug use reported as the 
most likely risk factor for infection, by year of notification and age group in years, 
2007-2017                                                                                                                                        
Source: HPSC                
Using NVRL person-based data from 1989-2004, HPSC notifications data from 2005-2009 and literature 
estimates for chronicity (75%) and mortality (13%), the total number of individuals living with diagnosed 
chronic hepatitis C in Ireland in 2009 was estimated to be 9,9138. There were an additional 6,707 notifications 
to HPSC between 2010 and 201758. After taking account of the notification of duplicates, resolved cases and 
deaths, approximately 15,000 people (0.3% of the population) were likely to have been diagnosed, and living, 
with chronic hepatitis C in Ireland by the end of 2017, most of whom were PWID or have injected drugs in the 
past.
The level of under-diagnosis of hepatitis C is not known in Ireland8. Studies in the UK indicate that around 
50% of cases of hepatitis C are not diagnosed59. If the situation in Ireland is similar, the total number of people 
living with chronic hepatitis C would be approximately 30,000. Diagnosis levels may be higher in Ireland, 
particularly in PWID, as access to OST and testing in OST services is reported to be very high. However, even 
if 75% of cases of hepatitis C in Ireland are diagnosed, the total estimated number of people living with 
hepatitis C would be 20,000. If 70% of these were people with a history of injecting drug use, this would 
equate to between 14,000 and 21,000 current or former drug users infected with hepatitis C. However, these 
estimates do not take account of the impact of hepatitis C treatment on the numbers currently infected. 
Hepatitis C treatment is discussed in section 5.1, box 1. 
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Mortality due to liver disease in people who use drugs
the irish national Drug-related Deaths index, 2004–2015
Established in 2005, the Irish National Drug-Related Deaths Index (NDRDI) is an epidemiological database 
which records all deaths by drug and alcohol poisoning, and deaths among people who use drugs and those 
who are alcohol dependent, using data from four sources: the Coroners Service, HIPE, the CTL and the General 
Mortality Register (GMR) from the Central Statistics Office (CSO). The NDRDI is maintained by the Health 
Research Board (HRB) and is jointly funded by the DoH and the Department of Justice and Equality.
Between 2004 and 2015, there were 187 non-poisoning deaths among people who used drugs where hepatitis 
C, hepatitis B or unspecified hepatitis were mentioned on the death certificate. This only includes deaths 
where hepatitis was mentioned on the death certificate and does not include deaths in those with a history of 
hepatitis infection where it was not mentioned on the death certificate. 
In total, 174 deaths involved hepatitis C. The number of hepatitis C deaths per year ranged from 9 to 25 with an 
average of 17. Hepatitis B was mentioned on the death certificate for 11 deaths, but most were in conjunction 
with hepatitis C. Ten deaths were due to unspecified hepatitis.  Cause of death is categorised by the NDRDI to 
enable presentation of the data in broad categories. Non-alcohol related liver disease was the most common 
cause of death (n=35, 19%) between 2004 and 2015. A further eighteen deaths (10%) were attributed to liver 
cancer (Personal communication: Dr Suzi Lyons, HRB – data is as of 31st May 2018 and is unpublished and 
provisional).
Modelled incidence of hepatitis C in drug users in ireland
A study was carried out in 2015 using HRB NDTRS data to estimate the incidence of injecting for drug users 
who entered drug treatment in Ireland between 1991 and 201460. The incidence of hepatitis C infection was 
then estimated by applying published incidence rates to the injecting curve (figure 9). Over this time period, 
over 14,000 injectors were registered on NDTRS. Almost three quarters were male and 94% injected an opioid, 
mostly heroin. There were an estimated 2,000 additional injectors who had never attended drug treatment 
services. Using published incidence rates of hepatitis C in PWID in Ireland and adjusting for those who never 
shared equipment, it was estimated that 12,000 PWID had been infected with hepatitis C (76%) by 2014 and 
that over 9,000 had become chronically infected. The incidence of hepatitis C infection increased rapidly in 
the 1980s and 1990s and peaked in 1998. Almost one third of those who became chronically infected had 
been infected for over 20 years by the end of 2014. 
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estimates of the prevalence and incidence of hepatitis C in drug users in ireland from published studies
Although available evidence suggests a declining incidence of injecting and of hepatitis C among drug users, 
prevalence studies indicate a considerable existing burden of disease. Studies of opioid users in Ireland 
between 1995 and 2018 estimated the hepatitis C prevalence in this population to be between 52% and 
84% (table 3). Of note, the prevalence in younger clients attending OST was lower in some recent studies30-31, 
providing further evidence of a decreasing incidence of hepatitis C among drug users in Ireland. Although 
several studies have been carried out assessing hepatitis C prevalence in PWID, most were carried out many 
years ago and the cohorts studied mostly attended Dublin-based addiction treatment centres or GPs. There 
is a lack of recent, nationally representative data on hepatitis C prevalence in PWID. 
box 1. Hepatitis C treatment in ireland
Between 1992 and 2014, hepatitis C was treated using injected interferon on its own or in combination 
with ribavirin, or with ribavirin and boceprevir or telaprevir.  Treatment uptake, particularly in PWID, 
was generally reported to be low25,29. Interferon-based treatment was associated with significant 
side effects, and sustained virological response (SVR) was only achieved for about half of those 
treated. In late 2014 and early 2015 new highly effective interferon-free oral treatments using direct 
acting antivirals (DAAs) became available in Ireland. Treatment with these newer drugs results in 
SVR (cure) for over 95% of patients32 and elimination of hepatitis C is now an achievable goal.
The HSE established a National Hepatitis C Treatment Programme (NHCTP) in 2015 in order to 
ensure that people living with hepatitis C in Ireland are offered effective antiviral drug regimens in 
a structured way that ensures quality and governance in keeping with international best practice 
(https://www.hse.ie/eng/about/who/primarycare/hepcprogramme%20.html). Information on all 
patients being treated, or being considered for treatment, is recorded in a National Hepatitis C 
Treatment Registry.
There are currently 4,455 patients included in this registry. Risk factor for acquisition of hepatitis 
C is recorded for two thirds of patients, and 77% of these are PWID. Between 2012 and mid-June 
2018, 1,652 PWID and three intranasal drug users were treated. Ninety percent of these patients 
were treated between 2015 and mid-2018. Treatment outcome is currently pending for 36% and 
a further 3% have been lost to follow-up. Of the remaining 1,007 treated patients, 91% (n=902) 
achieved SVR, 7% (n=72) stopped treatment early and 2% (n=15) did not achieve SVR (Personal 
communication: Michele Tait, National Hepatitis C Treatment Programme Manager, NHCTP, June 
2018). 
Improvements in screening, referral to appropriate services and treatment uptake among PWID 
are now needed. The NHCTP is developing different models for providing hepatitis C treatment in 
settings beyond the traditional hospital-based model in an attempt to extend treatment to hard 
to reach groups such as PWID. The programme has commenced a number of pilot sites in the OST 
setting to assess the feasibility, acceptability, sustainability and safety of providing treatment to 
PWIDs where they receive their methadone.
5.2 Hiv
HIV is a disease of major public health significance in Ireland and worldwide. It disproportionately affects 
certain population groups including PWID, MSM and migrants. Voluntary HIV testing has been available in 
Ireland since 1985 and NVRL provided data on HIV positive results to the Department of Health until 2001. 
In 2001, HPSC took over national reporting of HIV, and HIV case-based voluntary reporting was introduced in 
Ireland in 2003, with detailed information collected on risk group, age, sex, country of birth, co-infections and 
other epidemiological and clinical data. In 2011, HIV became a notifiable disease and was included in CIDR 
in 2012. 
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Diagnosed cases of Hiv
Hiv notifications, 1986 to 2017
Between 1985 and 2017, 1,645 diagnoses of HIV among PWID have been reported which account for 18.6% 
of total HIV notifications (figure 10). The data presented in Figure 10 are based on data reported to the DoH 
(1986-2000) and to HPSC (2001-2017). In the early 1980s, PWID were the population most affected by HIV 
in Ireland and accounted for over half of new diagnoses. In the 1990s, the number of new diagnoses among 
PWID fluctuated and accounted for between 21% and 47% of new diagnoses. Between 2004 and 2011, the 
number of diagnoses of HIV among PWID steadily decreased (from 74 to 17). An outbreak of HIV among PWID 
which occurred in Dublin in 2014/2015 resulted in 49 notifications among PWID in 2015 (see box 2). The 
number of notifications decreased to 21 in 2016 and 11 in 2017, accounting for 4% and 2% of total notifications 
respectively, although data for 2017 are provisional at the time of this report.  
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Figure 10. number of newly diagnosed Hiv cases in persons infected through injecting drug 
use, 1986 to 2017                                                                                                                                                                            
Source: HPSC
Latest data – 2003 to 2017
Since HIV case-based reporting began in 2003, 561 new diagnoses of HIV among PWID have been reported 
which accounts for 10% of all diagnoses in this time period. Of the 561 new diagnoses among PWID, 68% 
were among men and 32% among women (figure 11). 
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Figure 11. number of newly diagnosed Hiv cases in persons infected through injecting drug 
use by sex, 2003 to 2017
Source: HPSC
The average age at diagnosis in cases diagnosed from 2003 to 2017 was 32 years (range: 17 to 61 years). The 
number of new diagnoses among those aged less than 30 years has decreased since the early 2000s (figure 12). 
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Figure 12. number of newly diagnosed Hiv cases in persons infected through injecting 
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Source: HPSC
The majority (71%) of PWID diagnosed with HIV between 2003 and 2017 were born in Ireland with a further 
16% born in other European countries. Seventy three percent of PWID were co-infected with hepatitis C at the 
time of their HIV diagnosis. 
Between 2012 and 2017, 53% of PWID with HIV were diagnosed at a late stage of infection (i.e. their CD4 
count was ≤350 cells/µl at time of diagnosis). This compares with 44% diagnosed late in all other risk groups 
(excluding PWID). Eight percent of PWID newly diagnosed with HIV had an AIDS defining illness at the time 
of their HIV diagnosis. 
In 2016, NVRL carried out avidity testing on all new diagnoses of HIV to determine the proportion of diagnoses 
that are recent infections (infected within four months). The study found that overall 13% of HIV diagnoses in 
2016 were likely to be recent infections, with 26% of diagnoses among PWID likely to be recent61.  However, 
the actual number of recent infections (n=5) were small. This indicates on-going transmission of HIV among 
PWID.  HIV treatment is discussed in box 3.
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box 2. Hiv outbreak among PWiD in Dublin, 2014/2015
In early 2015, surveillance of HIV in the Department of Public Health in Dublin identified an increase in 
the number of acute cases of HIV (p24 antigen positive) among PWID. Drug treatment clinicians had 
also identified increased use of a new psychoactive substance (NPS), alpha-pyrrolidinovalerophenone 
(a-PVP), known as ‘snow blow’, which was being used by some PWID and which they suspected 
might be linked to the increase in HIV. A multi-disciplinary, intersectoral outbreak control team 
(OCT) was established by the Director of Public Health to investigate the outbreak, coordinate the 
outbreak response and advise on control measures61. 
From January 2014 to December 2015, 39 cases of recently acquired HIV among PWID were identified 
(figure 13). Fifty nine percent were male and the median age was 35 years (range: 20-51 years). The 
majority (74%) of cases were registered as homeless (94% of females and 61% of males). Seventy 
four percent were co-infected with hepatitis C. 
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Figure 13. number of new diagnoses in PWiD in Dublin, august 2013-December 2015
A case control study found that ‘snow blow’ was independently associated with HIV infection and 
there was a dose response effect38. In addition, sex with PWID and sharing needles were also 
independently associated with HIV infection. Key control measures included raising awareness 
among clinicians, addiction services and PWID, intensive case finding and contact tracing, early 
treatment of HIV infection in those most at risk, greater promotion of needle exchange, increased 
access to methadone treatment, frontline worker training and raising awareness about safe injecting 
and safe sex. Leaflets were distributed in hostels and settings in Dublin where patients/clients 
attended. 
The outbreak was declared over in February 2016. However, this population remains very vulnerable, 
with a potential for future HIV outbreaks particularly with the introduction of different types of 
NPS and the continuing homelessness situation. There is a need to maintain HIV testing in this 
population even when the risk of HIV is perceived as low. HIV outbreaks and an increase in HIV 
transmission among PWID have also occurred in a number of other European countries in recent 
years62-64.  Complacency about HIV infection has emerged as an important threat to the success 
of HIV prevention for PWID. Successful HIV prevention for PWID needs to include high OST, NSP 
and ART coverage and these need to be adapted to changes in the patterns of drug use. Particular 
attention should be paid to people who inject stimulants (e.g. cocaine and NPS), areas of deprivation, 
women and homeless PWID.
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Mortality due to Hiv/aiDs in people who use drugs
the irish national Drug-related Deaths index, 2004-2015 
According to data from the NDRDI, between 2004 and 2015 (most recent data available), there were 94 non-
poisoning deaths among people who used drugs where HIV/AIDS was mentioned on the death certificate. The 
number of deaths per year ranged from five to 13. This only includes deaths where HIV/AIDS was mentioned 
on the death certificate and does not include those with a history of HIV infection where it was not mentioned 
on the death certificate. Of those who died where HIV/AIDS was mentioned on the death certificate, 44 were 
co-infected with hepatitis C, 6 were co-infected with hepatitis B and four with unspecified hepatitis. The most 
common causes of death were HIV/AIDS related illnesses (43%), respiratory infection (19%) and liver disease 
(12%).
Hiv national surveillance 
Between 1986 and 2017, there were 233 deaths reported to the national surveillance system among PWID 
with HIV or AIDS (AIDS surveillance 1985-2001; HIV surveillance 2001-2017). The majority of these deaths 
(67%) occurred in the 1980s and 1990s before highly active antiretroviral therapy (HAART) became available. 
However, it should be noted that there is considerable under-reporting of deaths among those living with HIV 
and AIDS as deaths are usually only reported to Departments of Public Health if they occur at the time of HIV 
diagnosis (<5 deaths reported per year). 
estimates of the prevalence of Hiv in drug users in ireland from published studies
Table 3 describes HIV prevalence studies that have been carried out among PWID living in Ireland over a 20 
year period from 1997 to 2017. Depending on the population and setting chosen, the HIV prevalence rate in 
these studies varied from 1% to 19%. It is evident that certain areas within Dublin’s inner city have very high 
rates (19%) of HIV among PWID7. The most recent peer-reviewed study indicated a prevalence rate of 8%29. It 
is clear that although HIV prevalence among PWID has been measured by a number of studies, there is a lack 
of recent and nationally representative data. 
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box 3. Hiv treatment 
One of the priority actions in the National Sexual Health Strategy 2015-202055 is to “develop and 
implement guidance to support the appropriate use of antiretroviral therapy in HIV prevention.” The 
HSE Position on Antiretroviral Therapy (ART) for all people living with HIV (PLHIV)65 recommends 
that all people living with HIV attending HIV services in Ireland are offered ART and informed of the 
benefits of ART in improving their personal health and reducing HIV infectiousness (HIV Treatment 
as Prevention: TasP).
Continuum of Hiv care audit
The Continuum of HIV Care is a conceptual framework that enables countries to monitor the effective-
ness of key areas of their HIV programme. ECDC recommends a standardised monitoring approach 
in Europe, and developed definitions for monitoring the four priority stages: the number of PLHIV in 
the population; the number/proportion diagnosed; on ART; and virally suppressed36. These are in line 
with the UNAIDS 90-90-90 targets for 202066. 
In order to improve reporting in line with national obligations to ECDC and UNAIDS, HSE-SHCPP 
established a Continuum of HIV Care Steering Group, including relevant specialists and representa-
tion from all HIV treatment services in Ireland.  It was agreed that the UNAIDS Spectrum modelling 
software would be used to estimate the first two stages of the continuum i.e. the estimated number 
of people living with HIV, the number and proportion undiagnosed and the number diagnosed with 
HIV, and that a nationally coordinated audit of HIV treatment would be used to monitor the third and 
fourth stages i.e. the number on ART and the number virally suppressed.
HPSC worked with UNAIDS to develop the modelling estimates and HSE-SHCPP conducted the clin-
ical audit in collaboration with HIV services37. The results of the 4-stage continuum of HIV Care, com-
bining the modelling estimates for stages 1 and 2 with the HIV treatment audit results for stages 3 
and 4, are shown in figure 14.
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Figure 14. 4-stage Continuum of Hiv Care results for all people living with Hiv, 2017
Of the estimated 7,205 (95% CI: 6,456 - 8,056) people living with HIV, an estimated 87.1% have been 
diagnosed. Of the estimated 6,276 (95% CI: 5,623 - 7,017) people diagnosed with HIV, an estimated 
83.3% (95%CI: 74.5% - 93.0%) are on ART. Of the 5,227 people on ART, 95.4% are virally supressed 
(<200 copies per ml). Future work will involve refinement of the modelling and analysis by individual 
population groups, such as PWID.
In a study carried out in a Dublin hospital looking at the HIV continuum of care, results are available 
by risk group. Of a cohort of 1,000 patients attending the hospital from 1993 to 2014, 222 (22.2%) 
were PWID. Of the PWID, 75% (n=167) were found to be retained in care. Of those retained in care, 
93% (n=155) were on ART and of those on ART, 80% (n=124) were virally suppressed67. 
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5.3 Hepatitis b
Hepatitis B is a vaccine preventable viral infection. It primarily affects the liver. Less than 10% of people 
infected as adults develop chronic infection. The impact of chronic infection is similar to that of hepatitis C, 
with the patient at risk of cirrhosis of the liver, hepatocellular carcinoma (liver cancer) and liver failure68. 
Diagnosed cases of hepatitis b
Hepatitis b notifications, 2004-2017
Data from statutory notifications indicate that the incidence and prevalence of hepatitis B infection in PWID 
has been low in recent years. Fewer than five notified cases of hepatitis B have been attributed to injecting 
drug use annually between 2014 and 2017 (figure 15). Of 9,016 cases of hepatitis B notified between 2004 
and 2017, only 65 (<1%) were reported as likely to have been infected through injecting drug use and only five 
of these were reported to be acute infections.  This may be an underestimate due to incomplete reporting of 
risk factor information, particularly for chronic cases. However, the notifier and source of patient sample are 
recorded for most notifications and there is no evidence of significant numbers of cases of hepatitis B being 
diagnosed as a result of testing in the addiction services.
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Figure 15. number of notifications of hepatitis b with injecting drug use reported as the most 
likely risk factor for infection, by year of notification, 2006-2017                                                                                                                                                                      
Source: HPSC                    
                                                                                                                                                                 
estimates of the prevalence and incidence of hepatitis b in drug users in ireland from published studies
Results from studies in inner city areas in Dublin indicated a high prevalence of hepatitis B in early heroin 
injectors. A small cohort (n=82) of inner-city heroin injectors in Dublin was recruited for a study in 1985 and 
followed for 25 years27. Over 70% ultimately tested positive for hepatitis B antibodies (current or past infection). 
However, this was a particularly high-risk cohort: 9% of 15-24 year olds in this region of Dublin were estimated 
to be using heroin in 198110. Estimates from other studies in drug users in prison and treatment settings, 
carried out between 1997 and 2002, found a hepatitis B core antibody prevalence of between 14 and 28% 
(table 3). However, as the vast majority of people infected with hepatitis B as adults clear the infection and 
develop lifelong immunity, high antibody prevalence in early cohorts of drug users in Dublin did not translate 
to high prevalence of chronic infection. Where markers of current infection (hepatitis B surface antigen or DNA 
results) were reported, the prevalence ranged from 1-5% (table 3).  The low prevalence of chronic hepatitis 
B reported in studies of BBVs in addiction treatment settings supports the data from statutory notifications, 
indicating a low prevalence of chronic hepatitis B infection in people who use drugs in Ireland.
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table 3. summary of publications estimating the prevalence and incidence of hepatitis C, hepatitis b and Hiv in drug users in ireland
Year 
published, 
first author, 
ref num
Year of 
study or 
data
title summary
Hepatitis C antibody 
(current or past 
infection)
Hepatitis b antibody 
(current or past 
infection)
Hepatitis b surface 
antigen (current 
infection)
Hiv
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
1995, Smyth12 Aug 1992-
Aug 1993
Hepatitis C infection among 
injecting drug users attending 
the National Drug Treatment 
Centre
The prevalence of hepatitis C was determined in PWID 
attending the National Drug Treatment Centre in 
Dublin over a 1 year period. Those with a longer history 
of injecting had a higher HCV prevalence.
272 (NA) 229 (84%)
1997, 
Dorman69
HIV Risk Behaviour in Irish 
Intravenous Drug Users.
This study aimed to determine the prevalence of HIV 
along with the risk factors associated with acquiring 
HIV among PWID. Participants were interviewed and 
asked about their risk behaviours in the previous six 
months. A blood/saliva test was also obtained to 
determine HIV status. 
180 (97%) 15 (8%)
1998, Smyth13 1992-1997 Bloodborne viral infection in Irish 
injecting drug users
Cross-sectional survey to determine the prevalence 
of BBV infections and the associated risk factors in 
patients attending the National Drug Treatment Centre 
in Dublin. Older age, longer history of injecting, higher 
drug expenditure and commencing injecting before 
1990 were associated with higher risk of HCV and HIV 
infection. 
733 (96%) 453 (62%) 729 (96%) 7 (1%) 600 (79%) 7 (1%)
1999, Smyth15 July 1993-
Dec 1996
Evaluation of the impact of 
Dublin’s expanded harm 
reduction programme on 
prevalence of hepatitis C among 
short-term injecting drug users
New attenders at the National Drug Treatment Centre 
with an injecting history of less than 25 months, were 
tested for anti-HCV. Those who had been injecting for 
one year or less and those who commenced injecting 
after January 1994 had a lower prevalence of hepatitis C.
353 (NA) 184 (52%)
2000, 
Allwright16
Sept-Nov 
1998
Prevalence of antibodies to 
hepatitis B, hepatitis C, and HIV 
and risk factors in Irish prison-
ers: results of a national cross 
sectional survey
Anonymous survey using oral fluid samples to 
determine the prevalence of BBVs in prison inmates in 9 
of the 15 prisons in Ireland. Participation rate was 88% 
and 43% of participants had injected drugs. Only data 
for prisoners who inject drugs are presented here.
509 (NA) 414 (81%) 509 (NA) 94 (19%) 509 (NA) 18 (4%)
2001, 
Long17
1999 Prevalence of antibodies to 
hepatitis B, hepatitis C, and HIV 
and risk factors in entrants to 
Irish prisons: a national cross 
sectional survey
Anonymous survey using oral fluid samples to deter-
mine the prevalence of BBVs among entrants to 5 of the 
7 Irish committal prisons during a one month period. 
The participation rate was 97% and 29% of participants 
had injected drugs. . Only data for prisoners who inject 
drugs are presented here.
173 (NA) 124 (72%) 173 (NA) 31 (18%) 173 (NA) 10 (6%)
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Year 
published, 
first author, 
ref num
Year of 
study or 
data
title summary
Hepatitis C antibody 
(current or past 
infection)
Hepatitis b antibody 
(current or past 
infection)
Hepatitis b surface 
antigen (current 
infection)
Hiv
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
2001, 
Fitzgerald18
1997 Blood-borne infections in 
Dublin’s opiate users
A retrospective study of a random sample of patients 
attending five methadone clinics in the Eastern 
Health Board was carried out to assess BBV testing 
and prevalence, and hepatitis B vaccine coverage. 
The clinical records of 138 patients (20% sample) 
were reviewed. There was no information on hepatitis 
B vaccination or immunity for almost two thirds of 
patients.
99 (72%) 78 (79%) 64 (46%) 18 (28%) 79 (57%) 4 (5%) 90 (65%) 15 (17%)
2003, 
Cullen19 
1999 Hepatitis C infection among drug 
users attending general practice
The medical records of 571 patients attending 42 
general practices in the Eastern area for methadone 
maintenance were reviewed to assess BBV testing, 
prevalence and risk factors. Just under half of invited 
GPs participated in the study and their patient 
population represented 62% of patients attending GPs 
for methadone maintenance.
380 (67%) 276 (73%) 316 (55%) 43 (14%)
2003, 
Kavanagh20
2001 High morbidity expected from 
cirrhosis in injecting drug users
Hepatitis C prevalence was determined from the 
medical records of all patients attending two GPs in a 
community-based drug treatment clinic in the Eastern 
area. Hepatitis C antigen/RNA results were available 
for 84% (n=59) of those who tested antibody positive, 
and 66% (n=39) were chronically infected.
91 (NA) 70 (77%)
2003, 
Smyth21 
Nov 1992-
Sept 1998
Retrospective cohort study 
examining incidence of HIV and 
hepatitis C infection among 
injecting drug users in Dublin
The incidence of HCV and HIV were retrospectively 
determined for a cohort of drug users who originally 
tested negative for these viruses. Just under one third 
(n=100) had a follow-up test for HCV by the end of the 
study period and two thirds had seroconverted, giving 
an incidence rate of 66/100 person years at risk. One 
quarter (n=164) had a follow up test for HIV and 2 
(1.2%) had seroconverted, giving an incidence rate of 
0.7/100 person years at risk.
100 (32%) 67 (67%) 164 (25%) 2 (1.2%)
2004, 
Moloney22
1998-2001 Hepatitis C: Lower prevalence 
in young person’s addiction 
treatment programme than in 
adult programmes
Letter describing the lower prevalence of HCV among a 
cohort of 54 adolescent drug users attending a young 
person’s community-based treatment programme in 
Dublin, between 1998 and 2001. Almost two thirds 
smoked heroin, rather than injecting it. The prevalence 
of HCV was higher in those who injected (55%)
54 (NA) 15 (27%)
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Year 
published, 
first author, 
ref num
Year of 
study or 
data
title summary
Hepatitis C antibody 
(current or past 
infection)
Hepatitis b antibody 
(current or past 
infection)
Hepatitis b surface 
antigen (current 
infection)
Hiv
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
2005, 
Smyth23 
  Irish injecting drug users and 
hepatitis C: the importance of the 
social context of injecting
A cross-sectional study to determine the prevalence 
of hepatitis C in 242 PWID recruited from 10 addiction 
treatment centres in Dublin. All had injected in the 
previous 6 months and had not been previously 
tested for hepatitis C. Testing positive for hepatitis 
C was associated with the total number of lifetime 
injecting episodes. Patients who reported closer social 
relationships with other injecting drug users were at 
increased risk of infection.
159 (66%) 97 (61%)
2005, 
Grogan24
Dec 2001 
to Jan 
2002
Bloodborne virus infections 
among drug users in Ireland: 
a retrospective cross-sectional 
survey of screening, prevalence, 
incidence and hepatitis B 
immunisation uptake
This study assessed BBV screening and prevalence in 
358 patients attending specialist addiction treatment 
centres in the Dublin area. The incidence of BBV 
was also determined for patients who initially tested 
negative and had at least one follow-up test.23% of 
patients who had tested negative for HCV were re-
tested and 41% (11/27) had seroconverted - incidence of 
24.5/100 person years at risk.  21% of patients who had 
tested negative for HIV were re-tested and 7% (4/59)  
had seroconverted - incidence of 3.4/100 person years 
at risk. 
316 (88%) 207 (66%) 244 (68%) 42 (17%) 299 (84%) 6 (2%) 307 (86%) 33 (11%)
2006, Long7 2001 HIV infection among heroin users 
and area of residence
The aim of this study was to determine the prevalence 
of BBVs among heroin users in two areas of Dublin, 
Dublin 24 (suburban area) and Dublin 8 (area close 
to South inner-city) to establish whether area of 
residence was associated with BBV prevalence. Test 
results were extracted from an existing dataset of BBV 
results (derived using systematic sampling (25%) of the 
CTL). The cohort in Dublin 8 was found to have higher 
prevalence of BBVs. Unlinked drug-related behavioural 
data was extracted from NDTRS data on new entrants 
to treatment for heroin between 1997 and 2000. Heroin 
users in Dublin 8 were older, were more likely to have 
injected drugs, and were five times more likely to report 
cocaine as an additional problem drug. The researchers 
concluded that there could be an association between 
injecting cocaine and HIV infection in the cohort in 
Dublin 8.
58 (91%) 
 
 
92 (91%)
31 (53%) 
 
 
67 (73%)
53 (83%) 
 
80 (80%)
0  
 
1 (1.3%)
55 (86%) 
 
94 (93%)
1 (2%) 
 
18 (19%)
30
DRug -Rel ateD blo oDboRne vIRuSeS In IRel anD 2018
Year 
published, 
first author, 
ref num
Year of 
study or 
data
title summary
Hepatitis C antibody 
(current or past 
infection)
Hepatitis b antibody 
(current or past 
infection)
Hepatitis b surface 
antigen (current 
infection)
Hiv
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
2007, 
Cullen25 
  Management of hepatitis C 
among drug users attending 
general practice in Ireland: 
baseline data from the Dublin 
Area hepatitis C in general 
practice initiative
The aim of this study was to describe hepatitis C care 
among drug users attending general practice in the 
Dublin area prior to the implementation of clinical 
practice guidelines. Stratified random sampling was 
used to select 196 patients who were attending 25 
general practices for methadone maintenance. Their 
clinical records were examined to determine the 
prevalence of BBVs and progression along the care 
pathway. Of those who tested antibody positive, just 
over one third (n=34) were tested for antigen/RNA and 
of those tested, 85% (n=29) were chronically infected. 
Of those who were known to be chronically infected, 
only 10% had commenced anti-viral treatment. 
146 (77%) 104 (71%) 118 (62%) 13 (11%) 135 (71%) 14 (10%)
2009, 
Cullen26
  Chronic illness and 
multimorbidity among problem 
drug users: a comparative cross 
sectional pilot study in primary 
care.
A cross-sectional study of chronic illness and multi-
morbidity among problem drug users. The medical 
records of patients attending three large urban general 
practices in Dublin for methadone treatment were 
reviewed.
57 (NA) 38 (67%) 57 (NA) 8 (14%)
2014, 
Drummond28
2011 Study on the prevalence of 
drug use, including intravenous 
drug use, and blood-borne 
viruses among the Irish prisoner 
population
Cross-sectional study targeting all prisons and 
prisoners in Ireland. Included oral fluid samples for BBV 
testing. The overall participation rate was 42%. Data 
shown are for prisoners identified as PWID only. The 
prevalence of BBVs in those with a history of injecting 
heroin was higher (hepatitis C 54%, HIV 7%).
200 (97%) 83 (41.5%) 200 (97%) 12 (6%)
2017, 
Murtagh29
2016 Hepatitis C prevalence and 
management among patients 
receiving opioid substitution 
treatment in general practice in 
Ireland. 
This study assessed hepatitis C prevalence and 
management in a sample of 134 patients attending 14 
OST prescribing GPs in the Dublin North inner city area. 
Screening levels were high but follow up antigen/RNA 
testing levels were low. Data on hepatitis C antigen/
RNA testing was collected from half of the participating 
practices. 57% of HCV antibody positive patients in 
those practices had been tested and 74% of those 
tested were chronically infected. Hepatitis B results 
were reported as either anti-HBc or HBsAg positive and 
8% of patients tested positive for one, or both, of these 
markers. 
124 (93%) 95 (77%) 97 (72%) 8 (8%)
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Year 
published, 
first author, 
ref num
Year of 
study or 
data
title summary
Hepatitis C antibody 
(current or past 
infection)
Hepatitis b antibody 
(current or past 
infection)
Hepatitis b surface 
antigen (current 
infection)
Hiv
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
num tested 
(%)
num pos 
(%)
2017, 
Keegan30
2015 Prevalence and risk factors 
for hepatitis C viral infection 
amongst a cohort of Irish drug 
users attending a drug treatment 
centre for agonist opioid 
treatment (AOT)
Retrospective cross-section study to determine the 
prevalence of HCV and risk factors for infection among 
patients attending a Dublin north inner-city addiction 
clinic (Thompson Centre) for OST. The prevalence of 
HCV was high overall, but significantly lower in younger 
clients.
228 (95%) 145 (64%)
2018, 
Murphy31
Late 2014 
to early 
2015
Audit of Hepatitis C Testing and 
Referral in Addiction Treatment 
Centres in Community Health 
Organisation Area 7. 2016.
An audit of patient charts to assess HCV testing and 
prevalence in addiction treatment centres in CHO7 
was carried out in late 2014/early 2015. Forms were 
returned for 40% of the eligible population. Almost 
all were opioid users and 79% were current or past 
injectors. Results are presented for all patients and 
those who reported a history of injecting. Hepatitis C 
antigen/RNA testing had been carried out for 89% 
of the patients who tested HCV antibody positive and 
almost two thirds (65%) were chronically infected.
358 (95%) 
 
 
282 (97%)
235 (66%) 
 
 
222 (79%)
349 (91%)  
 
 
274 (94%)
49 (14%) 
 
 
46 (17%)
NA: not available
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Planned study on bbv screening and prevalence in ost settings
Although a significant number of studies have been carried out estimating the prevalence of BBVs in OST 
settings, most are over 15 years old and many were carried out in single site Dublin-based clinics. Available 
evidence indicates a declining incidence of BBVs in PWID, but updated, geographically representative 
estimates are now needed to establish if this is the case. A joint study by the ICGP and HPSC will be carried 
out in 2018/2019, with the aim of obtaining current estimates of screening for BBVs, and the prevalence of 
BBVs, in a nationally representative sample of patients attending OST. Advances in HCV treatment (DAAs, 
mobile elastography, less restrictive treatment criteria and movement of treatment into community-based 
services) have revolutionised the management of HCV infection.  This study will also seek information on 
the proportion of patients with chronic hepatitis C infection who have had fibroscans to assess their degree 
of liver fibrosis, the proportion who have been treated, and the proportion who have achieved SVR. Ethical 
approval from the ICGP Ethics Committee has been granted. (Personal communication: Dr Des Crowley, lead 
researcher.) 
Summary
PWID comprise the majority of diagnosed cases of hepatitis C in Ireland. There is a high 
prevalence of hepatitis C infection in PWID (52-84% anti-HCV positive), but available data from 
hepatitis C notifications and published studies indicate a decreasing incidence of hepatitis C in 
drug users in Ireland. This is likely to be due to a combination of education and harm reduction 
measures, in addition to changes in the types of drugs used and a decline in injecting. Highly 
effective DAA drugs have made hepatitis C elimination achievable in Ireland. Implementing 
the hepatitis C screening guidelines and the clinical guidelines for OST will be important in 
improving the proportion of cases diagnosed and treated.
Prevalence studies carried out over the last 20 years indicate a HIV prevalence in PWID of 
between 1-19% depending on the population and setting. There are relatively few data from 
recent or national prevalence studies of HIV in PWID in Ireland. Available data from HIV 
notifications indicate a decrease in new diagnoses of HIV in PWID in Ireland and an increase 
in the age at diagnosis. Some of the more recent studies in OST or prison settings show a 
reduction in prevalence.  Annual notifications of HIV among PWID were low in both 2016 and 
2017, and accounted for less than 5% of total HIV notifications. Among HIV notifications in 
PWID, more than two thirds were male and more than two thirds were born in Ireland.  The 
majority were co-infected with hepatitis C. An outbreak of acute HIV among homeless PWID in 
Dublin in 2014/2015 highlighted the ongoing vulnerability of this population to infection and 
future outbreaks. 
Available data from hepatitis B notifications and published studies indicate a low incidence 
and prevalence of acute and chronic hepatitis B in PWID in Ireland. This is likely to be due to 
immunity following infection or vaccination. However, hepatitis B vaccine coverage data are 
limited. There is no formal register to record uptake in most settings in which vaccination is 
delivered to PWID. Many of the studies in which vaccine uptake is recorded are based on self-
reported status.
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6. Sub-populations of drug users at high risk
People who inject drugs share intersecting characteristics and adverse circumstances throughout life that 
lead to considerable social exclusion70.  They are at greatly increased risk of additional experiences leading 
to further social exclusion such as homelessness and incarceration. PWID may also experience accelerated 
ageing and cognitive impairment, which can lead to increased risk taking behaviours and challenges in 
engaging in healthcare for BBVs.  MSM who use drugs also have an increased risk of acquiring BBVs.
6.1 Prisoners
bbv testing and vaccination in prisons
Every prisoner undergoes a committal health screen on entering prison. This is repeated for every committal 
and transfer. During that initial screening, information is gathered on drug use and BBV status, and BBV 
testing is offered. All prisoners are also offered hepatitis A and hepatitis B vaccinations. However, uptake of 
BBV screening and vaccination is sub-optimal and it could be argued that a health committal screen is not 
the best time to ask a prisoner to consider all of this. Many initially refuse but then return later and request 
screening. It is also very difficult to obtain data on the uptake of BBV screening, the prevalence of BBVs and 
the incidence of new infections within each prison service as this information is not recorded in an extractable 
way on the prison database system. Recruit prison staff (RPOs) and current serving staff now receive infection 
control and prevention education as part of the Irish Prison Service (IPS) continuous professional development 
(CPD) programme. This has created a greater awareness of best practice around infection control, making 
the prison environment a safer place in which to work. Box 4 describes the implementation of a peer to peer 
education initiative in Irish prisons.
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box 4. Peer to Peer education for prisoners
Community Based Health & First Aid (CBHFA) in Action was originally designed by the International 
Red Cross to be facilitated globally in communities in a simple and flexible way through the National 
Red Cross/Red Crescent Society of each of the 190 countries where the movement is present. Ireland 
is the first country in the world to introduce CBHFA through groups of special status Irish Red Cross 
Volunteer Inmates in a prison setting. It first began at Wheatfield Prison in June 2009 and following 
the success of the pilot, it was extended to ten prisons by 2013 and to all fourteen prisons in Ireland 
in 2014.
The programme takes place under a partnership between the Irish Red Cross (IRC), the IPS and 
Education & Training Boards Ireland (ETBI). It is a unique approach to raising community health and 
hygiene awareness and first aid in prison communities through peer to peer education.
The programme has recruited almost 800 IRC volunteer inmates since 2009 and benefits prisoners 
directly every day, in addition to staff and families of the prisoners. This project has shown that it can 
change the outlook of prisoners to become more proactive and positive towards developing their 
community for the better. There is noticeable improvement in trust, communication and relationships 
amongst prisoners and with staff.
Volunteers have been instrumental with regards to educating their peers in relation to infection 
prevention, control and awareness, by reducing stigma around HIV and testing, by promoting the 
message that it is important to know your status. These special status inmate volunteers bring what 
they have learned in the classroom back to the landings and through project work, posters, leaflet 
drops and talks raise community health and hygiene awareness and first aid in prison communities. 
This has resulted in an increase in prisoners requesting testing for STIs and BBVs. Prisoners now feel 
that they can request testing without being stigmatised by fellow inmates for doing so.
Peer to peer education carried out by inmate volunteers from the IRC was used in a study of point 
of care testing for HIV in three Irish prisons71. Following an extensive awareness campaign aimed at 
educating prison inmates about HIV and reducing the stigma associated with HIV, large scale point-
of-care HIV testing was offered in Wheatfield, Cloverhill and Mountjoy prisons over short time periods 
in 2010, 2012 and 2013, respectively. Prior to this study being carried out, it was estimated that only 
10% of prison inmates in Wheatfield were aware of their HIV status. Just over half of inmates were 
screened (n=741) and only one tested positive for HIV (0.1%). This study showed that peer to peer 
education worked well in terms of encouraging relatively high HIV testing uptake. However, no data 
were collected on risk factors for infection or reason for refusal, making it difficult to interpret the very 
low prevalence found amongst those tested71. 
2011 study of drug use and bbv in irish prisons
In a prison study carried out in 2011, 824 randomly selected prison inmates were asked about substance abuse 
in the previous year28. Almost one third (30%) reported heroin use, 29% reported powdered cocaine use and 
12% reported crack cocaine use. Overall, of prison inmates who were tested, 13% were positive for hepatitis C 
antibodies, 2% were HIV positive and 0.3% were chronically infected with hepatitis B. Of the prison inmates 
who had ever injected drugs, 41.5% (n=83) tested positive for hepatitis C antibodies and 6% tested positive 
for HIV. The prevalence of both viruses was higher in the subset of prisoners who injected heroin: 54% were 
positive for hepatitis C antibodies and 7% were positive for HIV. Although the prevalence of HIV was similar 
to that found in two previous prison studies carried out in 199817 and 199916 (4% and 6%), the prevalence of 
hepatitis C antibodies had decreased significantly compared to the earlier studies (81%, 72%). 
Hepatitis B results were not reported by injecting status in the 2011 study, but only 0.3% (n=2) of prison 
inmates tested positive for hepatitis B surface antigen, indicating that the prevalence of hepatitis B infection 
is very low in the prison population. Just over half (54%) of those with a history of injecting drug use reported 
having been vaccinated against hepatitis B, but a further 13% were unaware of their vaccination status, so this 
may be an underestimate. Almost one fifth of prison inmates with a history of injecting drugs tested positive 
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for hepatitis B antibodies in the two previous prison studies (19%16,18%17), so it is likely that a number of those 
with long-standing drug use may have been infected in the past, have resolved infection and have natural 
immunity to hepatitis B.
2017 study estimating the seroprevalence of untreated chronic hepatitis C in Mountjoy Prison
A cross sectional study of male prisoners in Mountjoy prison was carried out in 2017. Over 400 prisoners 
(n=422, 78% of total eligible) participated in the study. Ninety five percent were tested for hepatitis C.  Of 
those tested, 23% were HCV antibody positive with one quarter showing spontaneous clearance. Of those 
with chronic infection (persistent RNA > 6 months), 77% (n=53) had untreated active HCV infection and 23% 
(n=16) had an SVR post treatment giving a seroprevalence estimate for untreated chronic hepatitis C infection 
of 13%. 
Of those who tested hepatitis C antibody positive, 10 (11%) were co-infected with HIV and 6 (6%) had been 
infected with hepatitis B. The seroprevalence of hepatitis C among prisoners with a history of injecting drug 
use was 80%. On multivariate analysis, injecting drug use and having a history of receiving a non-sterile 
community tattoo were the only significant risk factors independently associated with hepatitis C acquisition 
(p=0.005, β=0.468). (Personal communication: Dr Des Crowley (lead author), study submitted for publication).
6.2 Homeless population
Homelessness has become a crisis in Ireland. The number of homeless adults in Dublin has increased from 
approximately 3,000 in 2015 to over 5,000 in 2018 (Dublin Regional Homeless Executive). Many homeless 
adults are now accommodated in emergency shelters on a night-by-night basis with little continuity of care 
(Focus Ireland).
Homeless adults who use drugs are a sub-population of drug users at particularly high risk of BBV infections. 
In a study carried out in the north inner-city area of Dublin in 2005, 356 homeless adults (70% response rate) 
were interviewed over a two week period72. Access to free healthcare was poor with just over half (55%) having 
a medical card. Sixty four percent of study participants reported illicit drug use and 55% reported heroin 
use in particular. Forty eight percent of participants were currently injecting drugs or had injected in the 
past. Access to harm reduction services was relatively poor. Over a quarter of current heroin injectors had not 
attended needle exchange in the previous six months and one third had not been vaccinated against hepatitis 
B. The self-reported prevalence of BBVs among the total study population (including those who did not use 
drugs) was 36% for hepatitis C, 6% for HIV and 5% for hepatitis B72. 
A follow up study was carried out in September 2013 and included just over 600 homeless adults in Dublin 
(n=538) and Limerick (n=63)73.  Access to free healthcare had significantly improved, with 77% of study 
participants having a medical card. Drug use amongst the homeless had increased, with over three quarters 
(78%) of the study population reporting illicit drug use. Polydrug use was very common (71% of current drug 
users). Just over half (52%) of the study population had used heroin and 68% of those with a history of heroin 
use were currently taking methadone. Forty three percent of participants were currently injecting drugs or 
had injected drugs in the past. Almost all of those who injected used heroin. The self-reported prevalence 
of BBVs in the Dublin cohort had decreased compared to the previous study: 28.5% positive for hepatitis C, 
3.6% positive for HIV and 4.8% positive for hepatitis B. None of the Limerick cohort reported testing positive 
for BBVs.
A further study was carried out in 2015 to establish to effectiveness of intensified HCV screening in homeless 
people attending Safetynet primary healthcare services in Dublin, and to determine the HCV prevalence in 
this population74. Over 600 individuals were offered testing and 88% accepted. Where results were available, 
40% (n=206) tested positive for hepatitis C antibody. Over half were not aware of their positive status prior to 
testing. Sixty percent of those referred to specialist care did not attend, with participants indicating barriers 
to treatment that included on-going drug use, mental health problems and lack of stable accommodation. 
The authors concluded that there was a need for outreach community-based treatment alongside the more 
traditional specialist services in order to provide appropriate care for the homeless population. 
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6.3 Men who have sex with men (MsM)
Chemsex
Sexualised drug use or chemsex involves the use of recreational drugs for or during sex. Chemsex commonly 
involves crystal methamphetamine (crystal meth), gamma-hydroxybutyrate/gamma-butyrolactone (GHB/
GBL) and mephedrone but may also include other drugs such as ketamine and cocaine. 
Chemsex among sub-groups of MSM is an emerging threat in Ireland and other countries, because of the 
direct effects of the drugs themselves, and because of an increased risk of transmission of HIV, hepatitis 
B and C and other STIs75-77. The use of GHB/GBL for chemsex has caused particular concern because of its 
association with physical dependence, potentially life-threatening withdrawal, overdose and death (box 5). 
There are also concerns about the emergence of injecting drug use during chemsex, often referred to as 
“slamming”.  
The MSM Internet Survey (MISI) 2015, with 3,090 respondents, found that 7% had used one or more of 
four drugs commonly associated with chemsex (GHB/GBL, crystal meth, mephedrone and ketamine) in the 
previous 12 months76. The use of chemsex drugs was found to be more common among younger men and HIV 
positive men. Two percent of respondents had ever injected drugs in their life.  
A survey of MSM attending the Gay Men’s Health Service in Baggot Street Dublin in 2016 found that 27% of 
respondents had engaged in chemsex in the previous 12 months, using one or more of the following drugs: 
GHB/GBL; crystal meth; mephedrone; ketamine; cocaine; NPS; other stimulants77. Of those who had engaged 
in chemsex, 9% reported that they had ever injected drugs for sex. GHB/GBL was the drug most commonly 
reported as being used for chemsex; over half (57%) of those who had engaged in chemsex had used GHB/
GBL. Almost one fifth of the men (17%) had lost consciousness as a consequence of engaging with chemsex. 
One in four (25%) reported that chemsex was impacting negatively on their lives and almost one third (31%) 
reported that they would like help or advice about chemsex. Those engaging in chemsex were more likely to 
have had more sexual partners , more partners for anal intercourse  and to have had anal intercourse without 
a condom. They were also twice as likely to report having been treated for gonorrhoea over the previous 12 
months than those who did not. Other STIs/HIV were not found to be independently associated with chemsex. 
There was a recent increase in the number of hepatitis C notifications identified as MSM58. Twenty nine cases 
were identified in 2016 and 17 in 2017, compared to an average of 7 per year between 2012 and 2015. Most 
were acute cases diagnosed through STI services. Two thirds were also HIV positive and 59% had other recent 
STIs. Information on chemsex is not requested on the hepatitis C enhanced surveillance form, so it is not 
known if this increase was related to chemsex. 
box 5. g Clinic
A qualitative study, carried out in 2017, looked at problem G (GHB/GHL) use in a small number of 
people  who socialised as part of the ‘gay scene’ in Dublin78. Participants commonly reported increased 
sexual desire and significantly reduced inhibitions and two reported other people having sex with 
them while they were unconscious as a result of taking G. 
In order to meet the needs of MSM engaging in sexualised drug use, the National Drug Treatment 
Centre established a ‘G’ clinic in 2017. This clinic has links with a community-based counselling 
service. They provide both inpatient and outpatient ‘G’ detoxes and received extra funding to expand 
the clinic in 2018. 
The national drugs strategy, Reducing Harm, Supporting Recovery 2017-2025, has recognised the 
need to develop specialist referral groups for MSM who may not otherwise attend traditional drug 
services49. Further information on services and supports available for people using GHB/GBL can be 
found at http://www.drugs.ie/ghb and http://man2man.ie/alcohol-drugs-cigarettes/g/ 
37
DRug -Rel ateD blo oDboRne vIRuSeS In IRel anD 2018
This report summarises what is known about BBVs in drug users in Ireland. Although there are some gaps in 
information, the focus on harm reduction and drug treatment appears to be working. Available data indicate a 
relatively high prevalence of hepatitis C in older opioid users, but a declining incidence of opioid use, injecting 
and hepatitis C.  The number of newly diagnosed cases of HIV in PWID has also declined in recent years and 
the incidence and prevalence of hepatitis B is low. OST seems to be fairly readily available and screening is 
generally reported to be good in the drug services. However, most of the studies of BBV prevalence in OST 
settings were carried out many years ago and focused on larger addiction treatment centres in the Dublin area. 
A much needed, nationally representative prevalence study of BBVs in OST settings is planned for 2018/2019.
The lack of computerisation in most HSE addiction clinics means that monitoring the uptake of BBV screening 
and test results, and hepatitis B vaccine uptake, is difficult. Aside from monitoring adherence to clinical 
guidelines, a computerised system would provide important data on the incidence and prevalence of BBVs in 
PWID in Ireland and would facilitate early detection of outbreaks or unusual events. There are plans to have 
all sites computerised and for the same system to be used by all relevant services. This, in conjunction with 
unique health identifiers, will facilitate linkage of the addiction services. There is already a good database 
system in use in the prison services, but a unique health identifier will also be useful in terms of linking prison 
and community addiction services. A key deficit in the prison database system, and in some databases used 
in addiction treatment clinics, is that laboratory results are scanned and saved as images. This information is 
not readily extractable for reporting. The prison database does include fields for recording laboratory results, 
but these are not routinely completed. 
The NDTRS provides detailed information on all drug users entering drug treatment in Ireland each year. 
This is essential for monitoring trends in the types of drugs used, mode of use and the demographics of drug 
users. The system can record if drug users have been tested for BBVs, but the test results are not recorded. 
This would be a useful addition to the dataset. 
Needle and syringe programmes and supervised injecting facilities are intentionally low-barrier services, with 
very little information requested from service users. However, this makes it difficult to accurately quantify the 
total number of service users, the number of needle/syringe packs provided to each user and to determine 
whether service users were able to obtain sufficient supplies to meet their needs. There is a need to expand 
and increase the accessibility of needle and syringe services. It would also be very useful to collect minimal 
demographic data and ensure that all service users are offered hepatitis B vaccination, screening for BBVs 
and referrals to drug treatment services. The lack of information on image and performance enhancing drug 
users and on PWID who are not in drug treatment, could also be partially rectified by collecting data from 
needle and syringe services. Furthermore, this type of information is required for reporting to EMCDDA and 
for monitoring key indicators in the WHO/ECDC hepatitis elimination plan.
The National Hepatitis C Treatment Programme has been successfully introduced in acute hospitals and 
has now commenced a number of pilot treatment sites in OST settings. Providing hepatitis C treatment to 
patients at sites they attend regularly for OST should significantly improve treatment uptake and adherence in 
drug users. Increased community-based treatment is very welcome and treatment through homeless shelter 
clinics and GPs may also be possible in the future. 
There is a now a need to implement the hepatitis C screening guidelines with a view to increasing diagnosis 
of hepatitis C in Ireland and linking patients to treatment as early as possible. This will help minimise the 
morbidity and mortality associated with hepatitis C and decrease transmission to others. There has been 
increasing recognition nationally and internationally of the profound effect of social exclusion, such as that 
experienced by PWID, on health and access to health care79. Although there have been improvements in 
health screening in the homeless and prison populations in Ireland in recent years, there is a need to continue 
to develop BBV prevention, screening and treatment services which meet the needs of socially excluded 
people and ensure equity of access and outcomes using an Inclusion Health approach80. 
7. Conclusions
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